PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24267366-6 2013 RESULTS: PAF stimulated a statistically significant release of histamine, interleukin-8, and tumor necrosis factor (0.001-0.1 mumol/L) that was comparable to that stimulated by substance P. Pretreatment with RUP (25 mumol/L) for 10 minutes inhibited this effect. Histamine 63-72 PCNA clamp associated factor Homo sapiens 9-12 27758758-11 2017 Rupatadine (1-10 microM), levocetirizine (1-10 microM), and desloratadine (10 microM) inhibited PAF-induced histamine release. Histamine 108-117 PCNA clamp associated factor Homo sapiens 96-99 23320562-1 2013 BACKGROUND: Platelet-activating factor (PAF) causes wheal and flare responses which are abrogated by H1-antihistamines giving rise to the hypothesis that PAF-induced wheal development is secondary to histamine release from dermal mast cells. Histamine 108-117 PCNA clamp associated factor Homo sapiens 12-38 23320562-1 2013 BACKGROUND: Platelet-activating factor (PAF) causes wheal and flare responses which are abrogated by H1-antihistamines giving rise to the hypothesis that PAF-induced wheal development is secondary to histamine release from dermal mast cells. Histamine 108-117 PCNA clamp associated factor Homo sapiens 40-43 23320562-1 2013 BACKGROUND: Platelet-activating factor (PAF) causes wheal and flare responses which are abrogated by H1-antihistamines giving rise to the hypothesis that PAF-induced wheal development is secondary to histamine release from dermal mast cells. Histamine 108-117 PCNA clamp associated factor Homo sapiens 154-157 20392487-5 2010 Cell-signaling pathways in PB-derived MCs in response to PAF were investigated by analyzing the effect of various inhibitors and the silencing of phospholipase C (PLC) mRNA on PAF-mediated histamine release. Histamine 189-198 PCNA clamp associated factor Homo sapiens 57-60 20392487-5 2010 Cell-signaling pathways in PB-derived MCs in response to PAF were investigated by analyzing the effect of various inhibitors and the silencing of phospholipase C (PLC) mRNA on PAF-mediated histamine release. Histamine 189-198 PCNA clamp associated factor Homo sapiens 176-179 20392487-6 2010 RESULTS: We show for the first time that PAF induces histamine release from human lung MCs and PB-derived MCs but not skin MCs. Histamine 53-62 PCNA clamp associated factor Homo sapiens 41-44 15693702-5 2005 PAF was originally characterized by inducing aggregation and secretion of serotonin and histamine from rabbit platelets. Histamine 88-97 PCNA clamp associated factor Homo sapiens 0-3 10711351-4 2000 Intranasal administration of PAF, 60 micrograms, induced an increased responsiveness to histamine, 200 micrograms per nostril, 6 h later. Histamine 88-97 PCNA clamp associated factor Homo sapiens 29-32 10482285-1 1999 The application of platelet-activating factor (PAF) to the nasal mucosa of humans has been shown to increase histamine-induced hyper-reactivity. Histamine 109-118 PCNA clamp associated factor Homo sapiens 19-45 10482285-1 1999 The application of platelet-activating factor (PAF) to the nasal mucosa of humans has been shown to increase histamine-induced hyper-reactivity. Histamine 109-118 PCNA clamp associated factor Homo sapiens 47-50 9618706-5 1998 Histamine interacts directly with the endothelial cells (EC) and induces permeability, a transient expression of P-selectin and the secretion of lipid mediators (e.g. PGI2, PAF and LTB4). Histamine 0-9 PCNA clamp associated factor Homo sapiens 173-176 9155831-0 1997 Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade. Histamine 35-44 PCNA clamp associated factor Homo sapiens 0-26 9155831-3 1997 The purpose of this study was to investigate the extent and possible mechanisms of PAF-induced histamine release in human skin in vivo with the use of dermal microdialysis. Histamine 95-104 PCNA clamp associated factor Homo sapiens 83-86 9155831-7 1997 RESULTS: PAF, but not lyso-PAF, caused statistically significant dose-related histamine release and wheal and flare reactions. Histamine 78-87 PCNA clamp associated factor Homo sapiens 9-12 9155831-12 1997 CONCLUSIONS: These data suggest that PAF induced histamine release from mast cells in intact human skin indirectly via neurogenic activation. Histamine 49-58 PCNA clamp associated factor Homo sapiens 37-40 9155831-13 1997 Further, on the intradermal injection of PAF histamine release and the skin responses, the wheal and the flare, are differentially regulated by neurogenic components. Histamine 45-54 PCNA clamp associated factor Homo sapiens 41-44 8872518-6 1996 Our data indicate that oxygen radicals induce a direct calcium independent release of histamine which is due to membrane pertubating processes during the first phase but also induce a specific reaction leading to a further indirect histamine liberation which is probably mediated by PAF. Histamine 232-241 PCNA clamp associated factor Homo sapiens 283-286 8689766-15 1996 Previous studies have suggested that the weal and flare response to PAF may be mediated in part by histamine release. Histamine 99-108 PCNA clamp associated factor Homo sapiens 68-71 8721524-2 1996 Anti-IgE-stimulated basophil histamine release was significantly reduced in urticaria patients (median 2.9% vs 15.1% in normal controls), whereas histamine release to A23187, FMLP, and PAF, as well as anti-IgE-induced LTC4 release, showed no differences in both groups. Histamine 146-155 PCNA clamp associated factor Homo sapiens 185-188 8689766-8 1996 The effects of the various antagonists of PAF-induced responses suggest that its effects too may be mediated via histamine, the similarity of the effects of terfenadine and doxepin on these responses indicating that the effects of doxepin may be due to its known antihistamine activity rather than to any specific PAF-antagonistic properties. Histamine 113-122 PCNA clamp associated factor Homo sapiens 42-45 7948439-1 1994 Ketotifen, a histamine (H1) antagonist, inhibits PAF-induced eosinophil accumulation and airway hyperreactivity. Histamine 13-22 PCNA clamp associated factor Homo sapiens 49-52 8682156-8 1996 This is the first report showing PAF production by gastric epithelial cells in response to histamine, VIP and carbachol. Histamine 91-100 PCNA clamp associated factor Homo sapiens 33-36 7531728-0 1995 Histamine release from human basophils induced by platelet activating factor: the role of extracellular calcium, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Histamine 0-9 PCNA clamp associated factor Homo sapiens 50-76 7531728-1 1995 Although we have demonstrated that platelet activating factor (PAF) directly induces histamine release from human basophils, other studies have failed to report similar effects. Histamine 85-94 PCNA clamp associated factor Homo sapiens 35-61 7531728-1 1995 Although we have demonstrated that platelet activating factor (PAF) directly induces histamine release from human basophils, other studies have failed to report similar effects. Histamine 85-94 PCNA clamp associated factor Homo sapiens 63-66 7531728-3 1995 The secretion of histamine induced by PAF was optimal when the cells were incubated in Ca2+ for 2 to 5 minutes, whereas it declined at longer time intervals up to 15 minutes. Histamine 17-26 PCNA clamp associated factor Homo sapiens 38-41 7531728-4 1995 If cytochalasin B (5 micrograms/ml) was coincubated with PAF (1 mumol/L) to enhance the secretory response, histamine release was maximal at time 0 and decreased in parallel with the time of the basophils" exposure to Ca2+, like 0.1 microgram/ml anti-IgE-induced histamine secretion but unlike 1 mumol/L formyl-methionyl-leucyl-phenylalanine-induced histamine secretion. Histamine 108-117 PCNA clamp associated factor Homo sapiens 57-60 7531728-4 1995 If cytochalasin B (5 micrograms/ml) was coincubated with PAF (1 mumol/L) to enhance the secretory response, histamine release was maximal at time 0 and decreased in parallel with the time of the basophils" exposure to Ca2+, like 0.1 microgram/ml anti-IgE-induced histamine secretion but unlike 1 mumol/L formyl-methionyl-leucyl-phenylalanine-induced histamine secretion. Histamine 263-272 PCNA clamp associated factor Homo sapiens 57-60 7531728-4 1995 If cytochalasin B (5 micrograms/ml) was coincubated with PAF (1 mumol/L) to enhance the secretory response, histamine release was maximal at time 0 and decreased in parallel with the time of the basophils" exposure to Ca2+, like 0.1 microgram/ml anti-IgE-induced histamine secretion but unlike 1 mumol/L formyl-methionyl-leucyl-phenylalanine-induced histamine secretion. Histamine 263-272 PCNA clamp associated factor Homo sapiens 57-60 7531728-5 1995 We found that there is synergy between interleukin-3 (1 to 3 ng/ml) and PAF (1 mumol/L) for secretion of histamine from human basophils (p < 0.05) and that GM-CSF (10 ng/ml) significantly (p < 0.02) potentiates the secretion of histamine activated by PAF (1 mumol/L). Histamine 105-114 PCNA clamp associated factor Homo sapiens 72-75 7531728-5 1995 We found that there is synergy between interleukin-3 (1 to 3 ng/ml) and PAF (1 mumol/L) for secretion of histamine from human basophils (p < 0.05) and that GM-CSF (10 ng/ml) significantly (p < 0.02) potentiates the secretion of histamine activated by PAF (1 mumol/L). Histamine 105-114 PCNA clamp associated factor Homo sapiens 257-260 7531728-5 1995 We found that there is synergy between interleukin-3 (1 to 3 ng/ml) and PAF (1 mumol/L) for secretion of histamine from human basophils (p < 0.05) and that GM-CSF (10 ng/ml) significantly (p < 0.02) potentiates the secretion of histamine activated by PAF (1 mumol/L). Histamine 234-243 PCNA clamp associated factor Homo sapiens 72-75 7531728-6 1995 Our results demonstrate that: (1) the kinetics of the interaction between Ca2+ and the activation pathway that leads to histamine secretion are central events in the release reaction elicited by PAF in human basophils, and (2) interleukin-3 and GM-CSF can potentiate the secretory response of human basophils stimulated by PAF. Histamine 120-129 PCNA clamp associated factor Homo sapiens 195-198 7531728-6 1995 Our results demonstrate that: (1) the kinetics of the interaction between Ca2+ and the activation pathway that leads to histamine secretion are central events in the release reaction elicited by PAF in human basophils, and (2) interleukin-3 and GM-CSF can potentiate the secretory response of human basophils stimulated by PAF. Histamine 120-129 PCNA clamp associated factor Homo sapiens 323-326 7532002-5 1995 Both VD and MC903 decreased PAF-increased expression of ICAM-1 on PMVECs, PMN chemotaxis to zymosan activated serum and histamine, and PMN aggregation induced by PAF significantly. Histamine 120-129 PCNA clamp associated factor Homo sapiens 28-31 8118633-4 1994 Levels of lyso-PAF correlated strongly with those of N-alpha-tosyl-L-arginine methyl ester (TAME)-esterase activity (rs = 0.82, p = 0.0001) and histamine (rs = 0.57, p = 0.002). Histamine 144-153 PCNA clamp associated factor Homo sapiens 15-18 8118633-6 1994 In subjects showing a late phase reaction, as indicated by symptoms and histamine release, we detected lyso-PAF along with TAME-esterase activity and histamine during the late phase reaction. Histamine 72-81 PCNA clamp associated factor Homo sapiens 108-111 8220870-5 1993 Intranasal aerosol administration of PAF, 30 or 60 micrograms per nostril to normal human subjects induced an increased responsiveness to inhaled histamine, 50 to 400 micrograms and bradykinin, 100 micrograms per nostril at 2, 6 and 24 h following PAF treatment. Histamine 146-155 PCNA clamp associated factor Homo sapiens 37-40 8373423-1 1993 Platelet activating factor (PAF) primes vascular actions of mediators such as histamine and stimulates human umbilical vein endothelial cells (HUVECs) to produce prostacyclin (PGI2), which is important for the regulation of vascular tone, perfusion and hemostasis. Histamine 78-87 PCNA clamp associated factor Homo sapiens 0-26 8373423-1 1993 Platelet activating factor (PAF) primes vascular actions of mediators such as histamine and stimulates human umbilical vein endothelial cells (HUVECs) to produce prostacyclin (PGI2), which is important for the regulation of vascular tone, perfusion and hemostasis. Histamine 78-87 PCNA clamp associated factor Homo sapiens 28-31 8373423-2 1993 We demonstrate that pretreatment of HUVECs with PAF enhances thrombin- or histamine-induced rises of cytosolic free Ca(++)-concentration and subsequent Ca(++)-dependent PGI2-synthesis. Histamine 74-83 PCNA clamp associated factor Homo sapiens 48-51 8373423-4 1993 This suggests cooperative effects of PAF on activation processes induced by thrombin or histamine in HUVECs. Histamine 88-97 PCNA clamp associated factor Homo sapiens 37-40 8220870-14 1993 Vitamin E pretreatment of subjects resulted in the attenuation of the PAF-induced hyperresponsiveness to histamine, and a decrease in ECP levels of the nasal lavage fluid. Histamine 105-114 PCNA clamp associated factor Homo sapiens 70-73 8213348-2 1993 Significant amounts of PAF were measured in the cellular fraction after treatment with thrombin (2 NIHu/ml), calcium ionophore A23187 (2 microM) and histamine (100 microM) (110.3 +/- 14.3, 80.7 +/- 19.2 and 119.2 +/- 22.4 pg/10(5) cells, respectively). Histamine 149-158 PCNA clamp associated factor Homo sapiens 23-26 7688778-8 1993 Similarly, 1-acyl-2-acetyl-GPC (0.1 to 10 mumol/L) caused a concentration-dependent inhibition of PAF-activated histamine secretion (inhibitory concentration of 50% approximately equal to 0.2 mumol/L). Histamine 112-121 PCNA clamp associated factor Homo sapiens 98-101 7694703-0 1993 Pharmacologic control of histamine release from human basophils induced by platelet-activating factor. Histamine 25-34 PCNA clamp associated factor Homo sapiens 75-101 7694703-1 1993 We studied the effect of several compounds that influence different cell activation steps on platelet-activating factor (PAF)-induced basophil histamine secretion. Histamine 143-152 PCNA clamp associated factor Homo sapiens 93-119 7694703-1 1993 We studied the effect of several compounds that influence different cell activation steps on platelet-activating factor (PAF)-induced basophil histamine secretion. Histamine 143-152 PCNA clamp associated factor Homo sapiens 121-124 7694703-3 1993 Rolipram (phosphodiesterase, PDE, isotype IV inhibitor; 0.1 nM-10 microM) potently inhibited histamine secretion activated by PAF, whereas SKF95654 (PDE III inhibitor; 0.01-10 microM) was ineffective. Histamine 93-102 PCNA clamp associated factor Homo sapiens 126-129 7694703-4 1993 The kinase inhibitor, staurosporine (0.1-100 nM), enhanced PAF-induced basophil histamine release, whereas the G-protein inhibitor, pertussis toxin (1 microgram/ml), had an inhibitory effect. Histamine 80-89 PCNA clamp associated factor Homo sapiens 59-62 7694703-5 1993 The specific lipoxygenase inhibitor, AA-861 (0.1-10 microM), inhibited PAF-activated histamine release, while the leukotriene A4 hydrolase inhibitor, bestatin (100 microM), had only a marginal effect. Histamine 85-94 PCNA clamp associated factor Homo sapiens 71-74 7694703-6 1993 Finally, the Ca2+ channel entry blockers, verapamil (3-30 microM) and zinc (1.5-50 microM), inhibited PAF-induced histamine release. Histamine 114-123 PCNA clamp associated factor Homo sapiens 102-105 1914619-9 1991 These results suggest a limited role for endogenous histamine for the effects of PAF. Histamine 52-61 PCNA clamp associated factor Homo sapiens 81-84 1322030-14 1992 The effects of PAF on myocardial function may be due to the activation of mediators (e.g., histamine). Histamine 91-100 PCNA clamp associated factor Homo sapiens 15-18 1582704-1 1992 Using human platelet-rich plasma (PRP) we found that histamine concentration-dependently potentiated platelet aggregation induced by platelet-activating factor (PAF). Histamine 53-62 PCNA clamp associated factor Homo sapiens 161-164 1582704-3 1992 Chloropyramine reduced the potentiating effect of histamine on PAF-induced platelet aggregation, and when it was coadministered with BN 52021, inducing 63% inhibition of PAF-induced aggregation, the histamine-potentiated PAF response was completely abolished. Histamine 50-59 PCNA clamp associated factor Homo sapiens 63-66 1819703-2 1991 Sch 37370 selectively inhibits PAF-induced aggregation of human platelets in vitro (IC50 = 0.6 microM), and in vivo inhibits PAF- and histamine-induced bronchospasm in guinea pigs with ED50 values of 6.0 and 2.4 mg/kg p.o., respectively. Histamine 134-143 PCNA clamp associated factor Homo sapiens 31-34 1695868-1 1990 Histamine H1-antagonists inhibit the weal-and-flare responses to the intradermal injection of platelet activating factor (PAF) in humans, and PAF response is reduced in histamine-depleted skin sites. Histamine 0-9 PCNA clamp associated factor Homo sapiens 122-125 1717478-0 1991 Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. Histamine 61-70 PCNA clamp associated factor Homo sapiens 28-31 1717478-3 1991 EC stimulated with histamine or thrombin coexpress two proadhesive molecules within minutes: granule membrane protein 140 (GMP-140), a member of the selectin family, and platelet-activating factor (PAF), a biologically active phospholipid. Histamine 19-28 PCNA clamp associated factor Homo sapiens 170-196 1717478-3 1991 EC stimulated with histamine or thrombin coexpress two proadhesive molecules within minutes: granule membrane protein 140 (GMP-140), a member of the selectin family, and platelet-activating factor (PAF), a biologically active phospholipid. Histamine 19-28 PCNA clamp associated factor Homo sapiens 198-201 2043925-8 1991 Several PAF antagonists, such as CV-3988, L-652,731 and Y-24,180 inhibited the histamine- and thrombin-induced neutrophil adherence in a concentration-dependent manner. Histamine 79-88 PCNA clamp associated factor Homo sapiens 8-11 2043925-16 1991 Our studies indicate that: (a) adherence of neutrophils to endothelial cells induced by histamine and thrombin is mediated by PAF production since PAF antagonists inhibited the adherence of neutrophils; and (b) neutrophils, not endothelial cells, are the target cells through which dexamethasone acts to inhibit adherence. Histamine 88-97 PCNA clamp associated factor Homo sapiens 126-129 1699986-0 1990 Basophil histamine release by platelet-activating factor in aspirin-sensitive subjects with asthma. Histamine 9-18 PCNA clamp associated factor Homo sapiens 30-56 1699986-1 1990 Histamine release induced by platelet-activating factor (PAF) from leukocytes of aspirin-sensitive subjects with asthma was higher than that from normal control subjects, despite the similarity of anti-IgE-induced histamine release. Histamine 0-9 PCNA clamp associated factor Homo sapiens 29-55 1699986-1 1990 Histamine release induced by platelet-activating factor (PAF) from leukocytes of aspirin-sensitive subjects with asthma was higher than that from normal control subjects, despite the similarity of anti-IgE-induced histamine release. Histamine 0-9 PCNA clamp associated factor Homo sapiens 57-60 1699986-2 1990 Moreover, basophils of some aspirin-sensitive subjects with asthma released histamine by PAF stimulation in the absence of cytochalasin B that affects histamine release and is required in PAF-induced histamine release from leukocytes of atopic subjects with asthma and normal control subjects. Histamine 76-85 PCNA clamp associated factor Homo sapiens 89-92 1699986-2 1990 Moreover, basophils of some aspirin-sensitive subjects with asthma released histamine by PAF stimulation in the absence of cytochalasin B that affects histamine release and is required in PAF-induced histamine release from leukocytes of atopic subjects with asthma and normal control subjects. Histamine 76-85 PCNA clamp associated factor Homo sapiens 188-191 1699986-2 1990 Moreover, basophils of some aspirin-sensitive subjects with asthma released histamine by PAF stimulation in the absence of cytochalasin B that affects histamine release and is required in PAF-induced histamine release from leukocytes of atopic subjects with asthma and normal control subjects. Histamine 151-160 PCNA clamp associated factor Homo sapiens 89-92 1699986-2 1990 Moreover, basophils of some aspirin-sensitive subjects with asthma released histamine by PAF stimulation in the absence of cytochalasin B that affects histamine release and is required in PAF-induced histamine release from leukocytes of atopic subjects with asthma and normal control subjects. Histamine 151-160 PCNA clamp associated factor Homo sapiens 89-92 1699986-3 1990 In addition to temperature dependency and inhibition by ethylenediaminetetraacetic acid reported previously, PAF-induced histamine release was enhanced by cytochalasin B and indomethacin and inhibited by dexamethasone. Histamine 121-130 PCNA clamp associated factor Homo sapiens 109-112 1699986-4 1990 These features are common with IgE-mediated histamine release and suggest the existence of the common pathway to PAF-induced histamine release and IgE-mediated histamine release. Histamine 44-53 PCNA clamp associated factor Homo sapiens 113-116 1699986-4 1990 These features are common with IgE-mediated histamine release and suggest the existence of the common pathway to PAF-induced histamine release and IgE-mediated histamine release. Histamine 125-134 PCNA clamp associated factor Homo sapiens 113-116 1699986-4 1990 These features are common with IgE-mediated histamine release and suggest the existence of the common pathway to PAF-induced histamine release and IgE-mediated histamine release. Histamine 125-134 PCNA clamp associated factor Homo sapiens 113-116 1699986-5 1990 The results in the present study indicate the pathophysiologic significance of PAF-induced histamine release and that activation of basophils by PAF may be relevant to the pathogenesis in some aspirin-sensitive subjects with asthma. Histamine 91-100 PCNA clamp associated factor Homo sapiens 79-82 1655549-2 1991 Maximal priming by PAF was observed when a 5-min interval separated the applications of 10(-9) M PAF and 10(-6) M histamine. Histamine 114-123 PCNA clamp associated factor Homo sapiens 19-22 1655549-12 1991 We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Histamine 86-95 PCNA clamp associated factor Homo sapiens 20-23 1655549-12 1991 We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Histamine 86-95 PCNA clamp associated factor Homo sapiens 268-271 1655549-12 1991 We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Histamine 201-210 PCNA clamp associated factor Homo sapiens 20-23 1655549-12 1991 We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Histamine 201-210 PCNA clamp associated factor Homo sapiens 268-271 1679658-2 1991 The role of histamine in PAF-induced acute inflammatory responses (flare and weal) in the skin has been evaluated in a series of three separate studies. Histamine 12-21 PCNA clamp associated factor Homo sapiens 25-28 1679658-9 1991 Intradermally injected PAF was associated with acute rises in plasma histamine in blood drawn from a draining vein with peak concentrations occurring within 5 min of injection. Histamine 69-78 PCNA clamp associated factor Homo sapiens 23-26 1679658-14 1991 It is concluded that histamine has an important role in the acute inflammatory responses to intradermally injected PAF, although there does appear to be a significant direct vascular component in the PAF-induced weal response. Histamine 21-30 PCNA clamp associated factor Homo sapiens 115-118 1711077-3 1991 In this study we examined the effect of PAF upon the release of histamine and leukotriene (LT) C4 by basophils when added alone and in combination with different agonists and cytokines. Histamine 64-73 PCNA clamp associated factor Homo sapiens 40-43 1711077-10 1991 IL-1 beta-pretreated basophils released minimal amounts of histamine in response to PAF. Histamine 59-68 PCNA clamp associated factor Homo sapiens 84-87 1711077-15 1991 Thus, depending on the presence of IL-3, GM-CSF, or IL-5, PAF is a potent basophil agonist capable of inducing histamine release as well as de novo synthesis of LTC4. Histamine 111-120 PCNA clamp associated factor Homo sapiens 58-61 1700998-3 1990 PAF (10 nM to 1 microM) caused a concentration-dependent, noncytotoxic histamine release (greater than or equal to 10% of total) in 27 of 44 subjects tested (24 atopic and 20 nonatopic donors). Histamine 71-80 PCNA clamp associated factor Homo sapiens 0-3 1700998-5 1990 Coincubation of PAF with cytochalasin B (5 micrograms/ml) enhanced the release of histamine induced by PAF and activated the release process in most donors (42 of 44). Histamine 82-91 PCNA clamp associated factor Homo sapiens 16-19 1700998-5 1990 Coincubation of PAF with cytochalasin B (5 micrograms/ml) enhanced the release of histamine induced by PAF and activated the release process in most donors (42 of 44). Histamine 82-91 PCNA clamp associated factor Homo sapiens 103-106 1700998-9 1990 The release of histamine activated by PAF was inhibited by the specific PAF receptor antagonist, L-652,731, with an IC50 of 0.4 microM. Histamine 15-24 PCNA clamp associated factor Homo sapiens 38-41 1700998-9 1990 The release of histamine activated by PAF was inhibited by the specific PAF receptor antagonist, L-652,731, with an IC50 of 0.4 microM. Histamine 15-24 PCNA clamp associated factor Homo sapiens 72-75 1700998-11 1990 If neutrophils were removed from the basophil preparation by a Percoll gradient or a countercurrent elutriation technique, there was a significant decrease in PAF-induced histamine release. Histamine 171-180 PCNA clamp associated factor Homo sapiens 159-162 1700998-13 1990 Finally, among human histamine-containing cells, the basophils are unique in degranulating following a PAF challenge. Histamine 21-30 PCNA clamp associated factor Homo sapiens 103-106 1695868-1 1990 Histamine H1-antagonists inhibit the weal-and-flare responses to the intradermal injection of platelet activating factor (PAF) in humans, and PAF response is reduced in histamine-depleted skin sites. Histamine 169-178 PCNA clamp associated factor Homo sapiens 142-145 1695868-3 1990 We have therefore studied the interaction of PAF with cutaneous mast cells by observing whether it releases histamine directly from human dispersed foreskin mast cells, potentiates the activity of known mast cell stimulants or liberates histamine releasing factors (HRFs) from human platelets and leucocytes to release mast cell histamine by an indirect mechanism. Histamine 108-117 PCNA clamp associated factor Homo sapiens 45-48 1695868-4 1990 At a concentration of 100 microM both PAF C18 and PAF C16 caused near maximal release (83.5 +/- 4.3% and 88.2 +/- 4.5% respectively) of the total histamine content of the cell. Histamine 146-155 PCNA clamp associated factor Homo sapiens 38-41 1695868-4 1990 At a concentration of 100 microM both PAF C18 and PAF C16 caused near maximal release (83.5 +/- 4.3% and 88.2 +/- 4.5% respectively) of the total histamine content of the cell. Histamine 146-155 PCNA clamp associated factor Homo sapiens 50-53 1695868-6 1990 These results indicate a cytotoxic mechanism of histamine release by PAF 100 microM. Histamine 48-57 PCNA clamp associated factor Homo sapiens 69-72 2615107-3 1989 After incubation with PAF at 10(-7) M, the contractions of pulmonary vascular smooth muscle induced by histamine and prostaglandin F2 alpha were significantly decreased. Histamine 103-112 PCNA clamp associated factor Homo sapiens 22-25 2512981-3 1989 In selenium-deficient HUVEC, histamine-induced PGI2 synthesis was significantly decreased when compared to selenium-supplemented HUVEC; in contrast, histamine-induced PAF production was increased by selenium deficiency. Histamine 149-158 PCNA clamp associated factor Homo sapiens 167-170 2707878-2 1989 As compared to the animals treated with solvent alone, guinea pigs receiving PAF (20 micrograms/kg/h, 15 days) exhibited a hyperresponsiveness to histamine that was not observed in those simultaneously treated with PAF and the PAF antagonist BN 52021. Histamine 146-155 PCNA clamp associated factor Homo sapiens 77-80 2707878-2 1989 As compared to the animals treated with solvent alone, guinea pigs receiving PAF (20 micrograms/kg/h, 15 days) exhibited a hyperresponsiveness to histamine that was not observed in those simultaneously treated with PAF and the PAF antagonist BN 52021. Histamine 146-155 PCNA clamp associated factor Homo sapiens 215-218 2707878-2 1989 As compared to the animals treated with solvent alone, guinea pigs receiving PAF (20 micrograms/kg/h, 15 days) exhibited a hyperresponsiveness to histamine that was not observed in those simultaneously treated with PAF and the PAF antagonist BN 52021. Histamine 146-155 PCNA clamp associated factor Homo sapiens 215-218 2759720-3 1989 Histamine had no direct chemoattractant effect on neutrophils but inhibited PAF-induced chemotaxis of neutrophils from healthy subjects and allergic asthmatics. Histamine 0-9 PCNA clamp associated factor Homo sapiens 76-79 6160567-3 1980 The authors recall the innermost mechanism of the main stages of histamine-release: recognition of membrane receptors, multiple enzymatic activations, opening of calcic membrane pores, synthesis of unpreformed mediators (SRSa and PAF), finally granular extrusion with release of histamine and of numerous mediators, among which the neutrophil chemotactic factor, one of the main responsible ones of the late phase of hypersensitivity phenomena. Histamine 65-74 PCNA clamp associated factor Homo sapiens 230-233 3288683-9 1988 Ketotifen inhibits PAF-induced wheal and flare in the skin, which is probably histamine dependent. Histamine 78-87 PCNA clamp associated factor Homo sapiens 19-22 3195800-9 1988 These results suggest that PAF-induced bronchoconstriction in humans is mediated at least in part by histamine release, not by cholinergic or cyclooxygenase-dependent mechanisms. Histamine 101-110 PCNA clamp associated factor Homo sapiens 27-30 2450844-0 1988 Histamine release from human leukocytes by platelet-activating factor. Histamine 0-9 PCNA clamp associated factor Homo sapiens 43-69 2450844-1 1988 Platelet-activating factor (PAF) was found to induce histamine release from human basophils in mixed leukocytes in the presence of cytochalasin B. Histamine 53-62 PCNA clamp associated factor Homo sapiens 0-26 2450844-1 1988 Platelet-activating factor (PAF) was found to induce histamine release from human basophils in mixed leukocytes in the presence of cytochalasin B. Histamine 53-62 PCNA clamp associated factor Homo sapiens 28-31 2450844-5 1988 PAF acted as an IgE-independent stimulus, but PAF-induced histamine release from leukocytes of allergic asthmatics, who had elevated serum IgE levels, was significantly higher than that from leukocytes of controls. Histamine 58-67 PCNA clamp associated factor Homo sapiens 46-49 2450844-6 1988 These results suggest that PAF-induced histamine release is useful for studying the role of PAF in the pathogenesis of allergic disorders including bronchial asthma. Histamine 39-48 PCNA clamp associated factor Homo sapiens 27-30 2450844-6 1988 These results suggest that PAF-induced histamine release is useful for studying the role of PAF in the pathogenesis of allergic disorders including bronchial asthma. Histamine 39-48 PCNA clamp associated factor Homo sapiens 92-95 3030311-3 1987 In the functional studies, a subthreshold dose of PAF (0.1 microM) significantly reduced the potency of isoproterenol to reverse methacholine or histamine-induced contraction. Histamine 145-154 PCNA clamp associated factor Homo sapiens 50-53 2408682-2 1985 It was found that within the concentration range of 10(-10) to 10(-7) M PAF and its analogs induce a moderate histamine release from the leukocytes. Histamine 110-119 PCNA clamp associated factor Homo sapiens 72-75 2408682-3 1985 However, at higher concentrations (greater than 10(-7) M) PAF induces an enhanced release of histamine from the leukocytes of allergic patients as compared to healthy individuals. Histamine 93-102 PCNA clamp associated factor Homo sapiens 58-61 2408682-4 1985 PAF and its analogs significantly potentiate the allergens-induced release of histamine from the leukocytes of allergic patients. Histamine 78-87 PCNA clamp associated factor Homo sapiens 0-3 2408682-5 1985 It was assumed that PAF induces the expression or demasking of additional numbers of IgE receptors on the surface of basophils, which leads tot he stimulation of histamine release from the leukocytes in the presence of allergens. Histamine 162-171 PCNA clamp associated factor Homo sapiens 20-23 2862164-0 1985 Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. Histamine 102-111 PCNA clamp associated factor Homo sapiens 43-69 33296106-7 2020 The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity, and also inhibits activation of human mast cells in response to PAF. Histamine 4-13 PCNA clamp associated factor Homo sapiens 74-77 33296106-7 2020 The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity, and also inhibits activation of human mast cells in response to PAF. Histamine 4-13 PCNA clamp associated factor Homo sapiens 152-155